Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome

American Journal of Gastroenterology

Volumn 110, Issue 2, 2015, Pages 310-319

  Lee, Chang Geun ^a   Lee, Jun Kyu ^a   Kang, Yun Seong ^a   Shin, Seungmin ^a   Kim, Jae Hak ^a   Lim, Yun Jeong ^a   Koh, Moon Soo ^a   Lee, Jin Ho ^a   Kang, Hyoun Woo ^a  

^a Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL OBESITY; ADULT; BODY MASS; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HEALTH CENTER; HEALTH PROMOTION; HUMAN; INTRAABDOMINAL FAT; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; ROME III CRITERIA; SUBCUTANEOUS FAT; TELEPHONE INTERVIEW; VISCERAL ADIPOSE TISSUE SUBCUTANEOUS ADIPOSE TISSUE RATIO; WAIST CIRCUMFERENCE;

EID: 84964300545     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.422     Document Type: Review

References (62)

1. Canale MP, Manca di Villahermosa S, Martino G et al. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol 2013; 2013: 865965.
2. Aggoun Y. Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res 2007; 61: 653-9.
3. Mensah GA, Mokdad AH, Ford E et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004; 22: 485-504
4. Donohoe CL, Pidgeon GP, Lysaght J et al. Obesity and gastrointestinal cancer. Br J Surg 2010; 97: 628-42.
5. Donohoe CL, O'Farrell NJ, Doyle SL et al. The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol 2014; 7: 38-50
6. Freeman HJ. Risk of gastrointestinal malignancies and mechanisms of cancer development with obesity and its treatment. Best Pract Res Clin Gastroenterol 2004; 18: 1167-75.
7. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: nonalcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013; 27: 195-208
8. Eslick GD. Gastrointestinal symptoms and obesity: a meta-analysis. Obes Rev 2012; 13: 469-79.
9. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol 2004; 99: 1807-14.
10. Delgado-Aros S, Locke GR 3rd, Camilleri M et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004; 99: 1801-6.
11. Talley NJ, Quan C, Jones MP et al. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. Neurogastroenterol Motil 2004; 16: 413-9.
12. Svedberg P, Johansson S, Wallander MA et al. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. Aliment Pharmacol Ther 2002; 16: 975-83.
13. Hausman DB, Loh MY, Flatt WP et al. Adipose tissue expansion and the development of obesity: infl uence of dietary fat type. Asia Pac J Clin Nutr 1997; 6: 49-55
14. Samaras K, Botelho NK, Chisholm DJ et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity 2010; 18: 884-9.
15. Mathieu P, Poirier P, Pibarot P et al. Visceral obesity: the link among infl ammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577-84.
16. Ghoshal UC, Abraham P, Bhatia SJ et al. Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study. Indian J Gastroenterol 2013; 32: 369-75.
17. Goodpaster BH. Measuring body fat distribution and content in humans. Curr Opin Clin Nutr Metab Care 2002; 5: 481-7.
18. Chung SJ, Kim D, Park MJ et al. Metabolic syndrome and visceral obesity as risk factors for refl ux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups. Gut 2008; 57: 1360-5.
19. Nam SY, Choi IJ, Ryu KH et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology 2010; 139: 1902-11 e2.
20. Armstrong D, Bennett JR, Blum AL et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92
21. Park MI. Is Rome III Criteria for irritable bowel syndrome more useful than Rome II Criteria in Korea? J Neurogastroenterol Motil 2010; 16: 342.
22. Park JM, Choi MG, Cho YK et al. Functional gastrointestinal disorders diagnosed by Rome III Questionnaire in Korea. J Neurogastroenterol Motil 2011; 17: 279-86.
23. Jung HK. Rome III Criteria for functional gastrointestinal disorders: is there a need for a better defi nition? J Neurogastroenterol Motil 2011; 17: 211-2.
24. Riegler G, Esposito I. Bristol scale stool form. A still valid help in medical practice and clinical research. Tech Coloproctol 2001; 5: 163-4.
25. van Oijen MG, Josemanders DF, Laheij RJ et al. Gastrointestinal disorders and symptoms: does body mass index matter? Neth J Med 2006; 64: 45-9.
26. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2013; 368: 578-9.
27. Simren M, Castedal M, Svedlund J et al. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci 2000; 45: 2151-61.
28. Kumar D, Wingate DL. The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 1985; 2: 973-7.
29. Whitehead WE, Holtkotter B, Enck P et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
30. Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specifi city, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-7.
31. Chang L. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011; 140: 761-5.
32. Locke GR 3rd, Weaver AL, Melton LJ 3rd et al. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 350-7.
33. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
34. Tornblom H, Lindberg G, Nyberg B et al. Full-thickness biopsy of the jejunum reveals infl ammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-9.
35. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients diff ers signifi cantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
36. Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-82.
37. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-801.
38. Foxx-Orenstein AE. Gastrointestinal symptoms and diseases related to obesity: an overview. Gastroenterol Clin North Am 2010; 39: 23-37
39. Crowell MD, Cheskin LJ, Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol 1994; 89: 387-91.
40. Revelo XS, Luck H, Winer S et al. Morphological and infl ammatory changes in visceral adipose tissue during obesity. Endocr Pathol 2014; 25: 93-101.
41. Ramalho R, Guimaraes C. [The role of adipose tissue and macrophages in chronic infl ammation associated with obesity: clinical implications]. Acta Med Port 2008; 21: 489-96.
42. Clement K, Vignes S. [Infl ammation, adipokines and obesity]. Rev Med Intern 2009; 30: 824-32.
43. Neels JG, Olefsky JM. Infl amed fat: what starts the fi re? J Clin Invest 2006; 116: 33-5.
44. Kintscher U, Hartge M, Hess K et al. T-lymphocyte infi ltration in visceral adipose tissue: a primary event in adipose tissue infl ammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1304-10.
45. Akiho H, Ihara E, Nakamura K. Low-grade infl ammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1: 97-105.
46. Spiller R, Garsed K. Infection, infl ammation, and the irritable bowel syndrome. Dig Liver Dis 2009; 41: 844-9.
47. Kristjansson G, Venge P, Wanders A et al. Clinical and subclinical intestinal infl ammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in infl ammatory bowel diseases and irritable bowel syndrome. Gut 2004; 53: 1806-12.
48. Erridge C, Attina T, Spickett CM et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial infl ammation Am J Clin Nutr 2007; 86: 1286-92.
49. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500-12.
50. Cox AJ, West NP, Cripps AW. Obesity, infl ammation, and the gut microbiota. Lancet Diabetes Endocrinol 2014; doi:10. 1016/S2213-8587(14)70134-2; e-pub ahead of print.
51. Parekh PJ, Arusi E, Vinik AI et al. The role and infl uence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome. Front Endocrinol 2014; 5: 47.
52. Mathur R, Amichai M, Chua KS et al. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J Clin Endocrinol Metab 2013; 98: E698-E702.
53. Turnbaugh PJ, Ley RE, Mahowald MA et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31.
54. Pimentel M, Lin HC, Enayati P et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1089-G1095.
55. Pimentel M, Kong Y, Park S. IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci 2004; 49: 84-7.
56. Chatterjee S, Park S, Low K et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007; 102: 837-41.
57. Lee JW, Park JH, Park DI et al. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci 2010; 55: 2922-8.
58. Lee H, Park JH, Park DI et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. J. Neurogastroenterol Motil 2013; 19: 244-50.
59. Shuffl ebotham J, Wetherell MA, Hince D et al. Women with diarrhoeapredominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. Stress 2009; 12: 30-6.
60. Xing J, Chen JD. Alterations of gastrointestinal motility in obesity. Obes Res 2004; 12: 1723-32.
61. Fu XY, Li Z, Zhang N et al. Eff ects of gastrointestinal motility on obesity. Nutr Metab 2014; 11: 3.
62. Elabd C, Chiellini C, Massoudi A et al. Human adipose tissue-derived multipotent stem cells diff erentiate in vitro and in vivo into osteocyte-like cells. Biochem Biophys Res Commun 2007; 361: 342-8.